Pro Nephro AKI (NGAL) is now FDA-Cleared     READ MORE

Announcements

October 10, 2024

Principal Investigator and CRO Named for US Adult Clinical Study

Dr. Andrew Allegretti, MD, MSC of Massachusetts General Hospital, has been appointed PI for the adult cutoff study and ProPharma has been selected as the CRO. Read More

Announcements

April 10, 2024

BioPorto Appoints Chief Legal Officer

Gry Louise Husby Larsen was appointed Executive Vice President and Chief Legal Officer (CLO). Read More

PRESS RELEASE

April 4, 2024

BioPorto Announces 2023 Annual Results; Releases Annual Report

2023 revenue growth attributed to a 25% increase in NGAL product sales. See the Annual Report for BioPorto’s strategic objectives and detailed action plan for the next 3-5 years. Read More

Announcements

April 2, 2024

Peter Mørch Eriksen Appointed Permanent Group CEO

BioPorto announces Peter Mørch Eriksen as permanent Group CEO after serving as interim CEO since January 2024. Read More

PRESS RELEASE

December 7, 2023

BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States

ProNephro AKI (NGAL) is the first Acute Kidney Injury (AKI) biomarker cleared for pediatric use (aged 3 months through 21 years) in the US and is designed to help doctors identify patients at risk of developing or having persistent, moderate-to-severe AKI. Read More

PRESS RELEASE

November 10, 2022

FDA De Novo Submission with Breakthrough Device Designation

BioPorto submitted an FDA De Novo application with Breakthrough Device Designation for an NGAL test to aid in identifying pediatric patients ≥ 3 months to < 22 years at risk of moderate to severe acute kidney injury.  Read More